Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357498 | 0.74 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL3322669 | 0.74 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15876480 | 0.72 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1719503 | 0.70 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6395827 | 0.69 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10707551 | 0.68 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL291929 | 0.67 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3095331 | 0.67 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15876482 | 0.66 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3322310 | 0.66 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550472-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1828189-A1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20060116372-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006056607-A1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116372-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.